HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT01947803

A Safety and Effectiveness Study of Paliperidone Palmitate in Chinese Patients With Schizophrenia

Researchers studied Paliperidone Palmitate, tracking side effects to assess safety and tolerability in people with schizophrenia.

Medication studyAges 18–65China
The study in practice

Understand this study

What did researchers investigate?

Researchers studied Paliperidone Palmitate, tracking side effects to assess safety and tolerability in people with schizophrenia.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
Baoding and 11 more locationsSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study clarity

Study information

Study start dateSeptember 2013
Recruitment status
Completed
Enrollment listed in the registry
353
Sponsor
Xian-Janssen Pharmaceutical Ltd.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
China
Age range
From 18 Years to 65 Years
Official registry ID
NCT01947803
Official title
Show the full official title

Safety and Effectiveness of Paliperidone Palmitate in 25-week Treatment on Chinese Patients With Schizophrenia: an Open-label, Single-arm, Multicenter Prospective Study

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Baoding · Beijing · Changsha

9 more locations
  • Chengdu
  • Guangzhou
  • Hangzhou
  • Kunming
  • Nanjing
  • Shijiazhuang
  • Taiyuan
  • Wuhan
  • Xi'an
Checked Official study record (opens in a new tab)
FAQ

Questions about this study

What did researchers investigate?

Researchers studied Paliperidone Palmitate, tracking side effects to assess safety and tolerability in people with schizophrenia.

Who is behind this study?

The study sponsor is Xian-Janssen Pharmaceutical Ltd., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including Paliperidone Palmitate.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me